

Amendments to the Claims

The following Listing of Claims replaces all prior versions and listings of claims in this application:

Listing of Claims:

1. (Currently Amended) A tablet for oral administration, comprising an effective amount of an active agent and at least 50% silicified microcrystalline cellulose, wherein said tablet is orally disintegratable within the range of 1 to 15 seconds.
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Currently Amended) The tablet according to ~~claim 4~~claim 1, wherein said tablet exhibits oral disintegratability in not less than 2 seconds.
6. (Canceled)
7. (Original) The tablet according to claim 1, wherein said silicified microcrystalline cellulose is contained in an amount within the range of 55% to 90%.
8. (Original) The tablet according to claim 7, wherein said silicified microcrystalline cellulose is contained in an amount within the range of 60% to 80%.
9. (Original) The tablet according to claim 1, wherein said active agent and said silicified microcrystalline cellulose together represent at least 80% of the tablet weight.
10. (Canceled)

11. (Original) The tablet according to claim 1, wherein said silicified microcrystalline cellulose contains 1-5% silicon dioxide.
12. (Original) The tablet according to claim 1, wherein said silicified microcrystalline cellulose has an average particle size within the range of 20-200 microns.
13. (Original) The tablet according to claim 12, wherein the median particle size is about 90 microns.
14. (Original) The tablet according to claim 1, which further comprises a disintegrant.
15. (Original) The tablet according to claim 14, wherein said disintegrant is selected from the group consisting of low substituted hydroxypropyl cellulose, carboxymethyl cellulose, crosscarmellose sodium, crosspovidone, starch, and combinations thereof.
16. (Original) The tablet according to claim 15, wherein said disintegrant is low substituted hydroxypropyl cellulose.
17. (Original) The tablet according to claim 14, wherein said disintegrant is contained in an amount of 0.5% to 20%.
18. (Original) The tablet according to claim 1, which does not contain an effervescent excipient.
19. (Original) The tablet according to claim 1, which has a hardness of 20N to 40N.
20. (Original) The tablet according to claim 1, which has a friability of less than 1%.
21. (Original) The tablet according to claim 1, wherein said tablet does not contain a water soluble binder.

22. (Original) The tablet according to claim 1, which further comprises at least one additional excipient selected from the group consisting of taste masking agents, sweeteners, lubricants, stabilizers, preservatives, and pH-adjustors.
23. (Original) The tablet according to claim 1, wherein said active agent is selected from the group consisting of pharmaceutical active agents, nutrients, nutraceuticals, and cosmetics.
24. (Original) The tablet according to claim 23, wherein said active agent is one or more vitamins.
25. (Original) The tablet according to claim 23, wherein said active agent is a pharmaceutically active agent.
26. (Original) The tablet according to claim 25, wherein said pharmaceutically active agent is present in the form of coated particles containing said pharmaceutically active agent.
27. (Original) The tablet according to claim 26, wherein said coating is an extended release or an enteric coating.
28. (Original) The tablet according to claim 25, wherein said pharmaceutically active agent is selected from the group consisting of anti-inflammatories, antirheumatics, antiemetics, analgetics, antiepileptics, antipsychotics, antidepressants, hypnotics, antiulcerics, prokinetic, antiasthmatics, anti-parkinsonics, cardiovasculars, vasodilators, urologics, hypolipidemics, antidiabetics, and antihistaminics.
29. (Original) The tablet according to claim 25, wherein said pharmaceutically active agent is selected from the group consisting of ibuprofen, acetaminophen, piroxicam, leflunomide, ondansetron, granisetron, paracetamol, carbamazepin,

lamotrigine, clozapine, olanzapine, risperidone, citalopram, paroxetine, sertraline, fluoxetine, fluvoxamine, zopiclon, zolpidem, cimetidine, ranitidine, omeprazole, metoclopramide, cisapride, domperidon, zafirlukast, montelukast, pramipexole, donepezil, selegiline, zolpidem, zopiclon, doxazosin, terazosin, atenolol, bisoprolol, amlodipine, nifedipine, diltiazem, enalapril, captopril, ramipril, losartan, glyceroltrinitrate, alfuzosin, finasteride, pravastatin, atorvastatin, simvastatin, gemfibrozil, pioglitazone, metformin, terfenadine, loratadine, celecoxib, rofecoxib, and rivastigmine.

30. (Original) A pharmaceutical orally disintegratable tablet which consists essentially of 50% to 90% silicified microcrystalline cellulose, 0% to 20% of low substituted hydroxypropyl cellulose, a lubricant, and an effective amount of a pharmaceutically active agent, wherein said tablet exhibits disintegration within 1 to 15 seconds when tested in an *in vitro* disintegration test.
31. (Original) The pharmaceutical tablet according to claim 30, wherein said tablet further comprises flavorants, colorants, or both.
32. (Currently Amended) A process of rapidly releasing an active agent from a solid tablet, which comprises disintegrating a tablet, which comprises at least 50% of a matrix of silicified microcrystalline cellulose and an effective amount of an active agent, by placing the tablet in a water environment for ~~up to 30~~ 1 to 15 seconds.
33. (Currently Amended) The process according to ~~claim 30~~ claim 32, wherein said water environment is a water-filled container.
34. (Currently Amended) In an orally disintegrating tablet which disintegrates in ~~30~~ 1-15 seconds or less and which comprises an active agent, the improvement of

which comprises providing a matrix of silicified microcrystalline cellulose in an amount of at least 50% within the tablet.

35. (Original) The orally disintegrating tablet according to claim 34, which does not contain a water soluble binder.
36. (New) The tablet according to claim 1, wherein said tablet exhibits oral disintegratability within the range of 1 to 10 seconds.
37. (New) The tablet according to claim 1, wherein said tablet exhibits oral disintegratability within the range of 1 to 2 seconds.